Viatris Inc Influvac ® revenue
Influvac ® revenue at Viatris Inc came to $90.6M for the quarter to 30 Sep 2026, down 27.8% from a year earlier.
As Viatris Inc reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 5 Nov 2026.
By quarter
| Period ending | Influvac ® revenue | Change on a year | Filed |
|---|---|---|---|
| 30 Sep 2026 | $90.6M | down 27.8% | 5 Nov 2026 |
| 30 Sep 2025 | $125.4M | up 3.4% | 6 Nov 2025 |
| 30 Sep 2024 | $121.3M | down 11.6% | 7 Nov 2024 |
| 30 Sep 2023 | $137.2M | down 13.9% | 8 Nov 2023 |
| 30 Sep 2022 | $159.3M | down 1.2% | 7 Nov 2022 |
| 30 Sep 2021 | $161.2M | — | 8 Nov 2021 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Viatris Inc: Brands revenue · Generics revenue · Lipitor revenue · Norvasc revenue · EpiPen® Auto-Injectors revenue · Lyrica ® revenue · Creon ® revenue · Viagra ® revenue · Zoloft ® revenue · Yupelri ® revenue · Celebrex ® revenue · Effexor ® revenue · Xalabrands revenue · Xanax ® revenue · Amitiza ® revenue · Dymista ® revenue · Developed Markets Segment revenue · Greater China revenue · Emerging Markets Segment revenue · Japan, Australia and New Zealand Segment revenue · financial statements
Every KPI and segment of VTRS, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
